Generic Movantik Availability
Last updated on Apr 10, 2025.
Movantik is a brand name of naloxegol, approved by the FDA in the following formulation(s):
MOVANTIK (naloxegol oxalate - tablet;oral)
-
Manufacturer: VALINOR
Approval date: September 16, 2014
Strength(s): EQ 12.5MG BASE [RLD], EQ 25MG BASE [RLD]
Is there a generic version of Movantik available?
No. There is currently no therapeutically equivalent version of Movantik available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Movantik. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Chemically modified small molecules
Patent 7,786,133
Issued: August 31, 2010
Inventor(s): Bentley; Michael D. et al.
Assignee(s): Nektar Therapeutics (San Carlos, CA)The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer obtained from a monodisperse or bimodal water-soluble oligomer composition. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.
Patent expiration dates:
- September 16, 2028✓✓
- September 16, 2028
-
Crystalline naloxol-peg conjugate
Patent 9,012,469
Issued: April 21, 2015
Inventor(s): .ANG.slund; Bengt Leonard et al.
Assignee(s): AstraZeneca AB (Sodertalje, SE); Nektar Therapeutics (San Francisco, CA)Naloxol-polyethlyene glycol conjugates of the formula: are provided in oxalate or phosphate salt forms including crystalline forms. Methods of preparing the salt forms and pharmaceutical compositions comprising the salt forms are also provided.
Patent expiration dates:
- April 2, 2032✓✓
- April 2, 2032
More about Movantik (naloxegol)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (265)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: peripheral opioid receptor antagonists
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
